Vaccine plus KRAS G12C inhibitor for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial combines a vaccine called CIMAvax-EGF with a KRAS G12C inhibitor to treat advanced lung cancer with a specific genetic change. The goal is to see if adding this vaccine helps the targeted therapy work better or longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced non-small cell lung cancer with a specific KRAS G12C mutation (a genetic change in the tumor).
- You must be able to receive standard KRAS G12C inhibitor treatment (like sotorasib or adagrasib).
- You should be generally well enough to carry out daily activities (performance status of 0-2).
- Your kidney and liver function must be within acceptable limits, and your blood counts must be adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
This Phase 1 study tests a KRAS-targeted vaccine combined with chemo and immunotherapy (nivolumab and ipilimumab) for people with advanced non-small cell lung cancer. It aims to help the immune system recognize and fight tumors with specific KRAS mutations, and to see if the treatment is safe and effective enough to study further.
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
This trial tests a new combination of two drugs (fulzerasib and ivonescimab) for people with a specific gene change (KRAS G12C) in their advanced lung cancer. It aims to see if this combination is safe and effective as the first treatment for this type of cancer.
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
This trial tests a vaccine that targets a specific genetic change (KRAS mutation) in advanced solid tumors like pancreatic and lung cancer. The vaccine is designed to help your immune system fight cancer cells with this mutation.
Hear when a new Advanced Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.